Yu Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Guo has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Xiaowu Dong
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
4 shared publications - Feng Zhu
Zhejiang University
2 shared publications Haibin Dai
Department of Pharmacy
2 shared publicationsHaiying Ding
Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences , Hangzhou, Zhejiang 310022
2 shared publications- Jinxin Che
Zhejiang University
2 shared publications Liteng Shen
Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
2 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
ADCdb 2.0: clinical landscape and ADMET profiles of antibody–drug conjugates
Systematically characterizing antibody-drug conjugates (ADCs) is essential for understanding their therapeutic properties, guiding molecular design, and supporting clinical development. Recently, the expanding clinical landscape of ADCs has generated extensive information on target antigens, therapeutic indications, and clinical trial pipelines, providing a valuable foundation for informing ADC development strategies. Moreover, ADMET profiles are critical for understanding the in vivo disposition, efficacy, and safety of ADCs. Integrating these accumulating clinical and pharmacological data is therefore necessary to enrich the evidence available for ADC development. In this study, ADCdb was updated to provide (i) detailed clinical landscape information for 542 ADCs, together with >3000 manually curated clinical trials from registries across nine registries and clinical trial platforms; (ii) >4000 ADMET profiles, including quantitative pharmacokinetic parameters and descriptive annotations supported by relevant references; and (iii) expanded pharmacological information and biological activity data comprising 13 088 ADC entries and 24 821 activity records, as well as ADC-specific functional annotations for 389 ADCs. Interactive visualization tools and antigen- and disease-centered search modules further enable systematic exploration of ADC composition, therapeutic indications, and clinical development. ADCdb 2.0 is expected to serve as a valuable resource for rational optimization of ADCs, and is accessible at https://idrblab.org/adcdb/
- 20 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
Open AccessADCdb 2.0: clinical landscape and ADMET profiles of antibody–drug conjugates
Systematically characterizing antibody-drug conjugates (ADCs) is essential for understanding their therapeutic properties, guiding molecular design, and supporting clinical development. Recently, the expanding clinical landscape of ADCs has generated extensive information on target antigens, therapeutic indications, and clinical trial pipelines, providing a valuable foundation for informing ADC development strategies. Moreover, ADMET profiles are critical for understanding the in vivo disposition, efficacy, and safety of ADCs. Integrating these accumulating clinical and pharmacological data is therefore necessary to enrich the evidence available for ADC development. In this study, ADCdb was updated to provide (i) detailed clinical landscape information for 542 ADCs, together with >3000 manually curated clinical trials from registries across nine registries and clinical trial platforms; (ii) >4000 ADMET profiles, including quantitative pharmacokinetic parameters and descriptive annotations supported by relevant references; and (iii) expanded pharmacological information and biological activity data comprising 13 088 ADC entries and 24 821 activity records, as well as ADC-specific functional annotations for 389 ADCs. Interactive visualization tools and antigen- and disease-centered search modules further enable systematic exploration of ADC composition, therapeutic indications, and clinical development. ADCdb 2.0 is expected to serve as a valuable resource for rational optimization of ADCs, and is accessible at https://idrblab.org/adcdb/
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 19871-19892
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are at the forefront of next-generation targeted cancer therapies, owing to their high specificity and potent cytotoxicity. The linker within ADCs plays a critical role in balancing efficacy and safety. Cleavable peptide linkers, dominating clinical-stage ADC design due to their capacity for selective drug release, nonetheless face challenges such as structural homogeneity, limited mouse plasma stability, and insufficient hydrophobicity improvement. Consequently, developing novel peptide linkers with enhanced stability, selectivity, and physicochemical properties is a key research focus. Here, by highlighting the cleavable peptide linkers used in clinical-stage ADCs and summarizing novel strategies in next-generation linker designs, we provide a timely overview of advances in peptide linkers, covering new peptide or peptidomimetic sequences, exolinker strategies, dual-cascade triggering mechanisms, and hydrophilic modifications. This review aims to offer a theoretical foundation and research insights for innovative linker design, thereby advancing next-generation ADCs to meet the growing demand for precision therapies.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 19871-19892
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are at the forefront of next-generation targeted cancer therapies, owing to their high specificity and potent cytotoxicity. The linker within ADCs plays a critical role in balancing efficacy and safety. Cleavable peptide linkers, dominating clinical-stage ADC design due to their capacity for selective drug release, nonetheless face challenges such as structural homogeneity, limited mouse plasma stability, and insufficient hydrophobicity improvement. Consequently, developing novel peptide linkers with enhanced stability, selectivity, and physicochemical properties is a key research focus. Here, by highlighting the cleavable peptide linkers used in clinical-stage ADCs and summarizing novel strategies in next-generation linker designs, we provide a timely overview of advances in peptide linkers, covering new peptide or peptidomimetic sequences, exolinker strategies, dual-cascade triggering mechanisms, and hydrophilic modifications. This review aims to offer a theoretical foundation and research insights for innovative linker design, thereby advancing next-generation ADCs to meet the growing demand for precision therapies.
- 12 July 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (14) , 11712-11731
Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers
Ferroptosis is a promising therapeutic target for injury-related diseases, yet diversity in ferroptosis inhibitors remains limited. In this study, initial structure optimization led us to focus on the bond dissociation enthalpy (BDE) of the N-H bond and the residency time of radical scavengers in a phospholipid bilayer, which may play an important role in ferroptosis inhibition potency. This led to the discovery of compound D1, exhibiting potent ferroptosis inhibition, high radical scavenging, and moderate membrane permeability. D1 demonstrated significant neuroprotection in an oxygen glucose deprivation/reoxygenation (OGD/R) model and reduced infarct volume in an in vivo stroke model upon intravenous treatment. Further screening based on this strategy identified NecroX-7 and Eriodictyol-7-O-glucoside as novel ferroptosis inhibitors with highly polar structural characteristics. This approach bridges the gap between free radical scavengers and ferroptosis inhibitors, providing a foundation for research and insights into novel ferroptosis inhibitor development.
- 12 July 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (14) , 11712-11731
Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers
Ferroptosis is a promising therapeutic target for injury-related diseases, yet diversity in ferroptosis inhibitors remains limited. In this study, initial structure optimization led us to focus on the bond dissociation enthalpy (BDE) of the N-H bond and the residency time of radical scavengers in a phospholipid bilayer, which may play an important role in ferroptosis inhibition potency. This led to the discovery of compound D1, exhibiting potent ferroptosis inhibition, high radical scavenging, and moderate membrane permeability. D1 demonstrated significant neuroprotection in an oxygen glucose deprivation/reoxygenation (OGD/R) model and reduced infarct volume in an in vivo stroke model upon intravenous treatment. Further screening based on this strategy identified NecroX-7 and Eriodictyol-7-O-glucoside as novel ferroptosis inhibitors with highly polar structural characteristics. This approach bridges the gap between free radical scavengers and ferroptosis inhibitors, providing a foundation for research and insights into novel ferroptosis inhibitor development.
- Open Access
- 13 October 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1097-D1109
ADCdb: the database of antibody–drug conjugates
Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which, via their antibody (mAb) component, deliver and release their potent warhead (a.k.a. payload) at the disease site, thereby simultaneously improving the efficacy of delivered therapy and reducing its off-target toxicity. To design ADCs of promising efficacy, it is crucial to have the critical data of pharma-information and biological activities for each ADC. However, no such database has been constructed yet. In this study, a database named ADCdb focusing on providing ADC information (especially its pharma-information and biological activities) from multiple perspectives was thus developed. Particularly, a total of 6572 ADCs (359 approved by FDA or in clinical trial pipeline, 501 in preclinical test, 819 with in-vivo testing data, 1868 with cell line/target testing data, 3025 without in-vivo/cell line/target testing data) together with their explicit pharma-information was collected and provided. Moreover, a total of 9171 literature-reported activities were discovered, which were identified from diverse clinical trial pipelines, model organisms, patient/cell-derived xenograft models, etc. Due to the significance of ADCs and their relevant data, this new database was expected to attract broad interests from diverse research fields of current biopharmaceutical drug discovery. The ADCdb is now publicly accessible at: https://idrblab.org/adcdb/.
- 13 October 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1097-D1109
Open AccessADCdb: the database of antibody–drug conjugates
Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which, via their antibody (mAb) component, deliver and release their potent warhead (a.k.a. payload) at the disease site, thereby simultaneously improving the efficacy of delivered therapy and reducing its off-target toxicity. To design ADCs of promising efficacy, it is crucial to have the critical data of pharma-information and biological activities for each ADC. However, no such database has been constructed yet. In this study, a database named ADCdb focusing on providing ADC information (especially its pharma-information and biological activities) from multiple perspectives was thus developed. Particularly, a total of 6572 ADCs (359 approved by FDA or in clinical trial pipeline, 501 in preclinical test, 819 with in-vivo testing data, 1868 with cell line/target testing data, 3025 without in-vivo/cell line/target testing data) together with their explicit pharma-information was collected and provided. Moreover, a total of 9171 literature-reported activities were discovered, which were identified from diverse clinical trial pipelines, model organisms, patient/cell-derived xenograft models, etc. Due to the significance of ADCs and their relevant data, this new database was expected to attract broad interests from diverse research fields of current biopharmaceutical drug discovery. The ADCdb is now publicly accessible at: https://idrblab.org/adcdb/.
- 1 May 1990
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 258 (5) , G803-G809
Molecular characterization of bombesin receptors on rat pancreatic acinar AR42J cells
A biologically active, chemically defined, radioactive ligand was used for characterizing bombesin (BBS) receptors on rat pancreatic acinar cancer cells (AR42J). [Tyr4]BBS, iodinated with enzymobeads and fractionated by high-performance liquid chromatography, was monitored for biological activity as evidenced by gastrin release from perfused isolated rat stomach. The monoiodinated peptide peak was greater than 95% biologically active, with a specific activity of greater than 2,000 disintegrations.min-1.fmol-1. The maximum number of BBS receptors per cell were measured at 30 degrees C after 20-25 min of incubation; binding was submaximum at temperatures lower or higher than 30 degrees C. A single class of high-affinity binding sites (Kd = 1.77 +/- 0.21 nM) was identified for BBS on AR42J cells and nonspecific binding was less than 20-30% at all points. A total of 1.47 +/- 0.14 x 10(5) specific BBS binding sites per cell were measured that were specific for BBS and gastrin-releasing peptide (GRP) analogues. Iodinated GRP-(1-27) was cross-linked to BBS receptors on AR42J cells using several bifunctional cross-linking reagents followed by polyacrylamide gel electrophoresis of the solubilized receptor complex under reducing and nonreducing conditions. A densitometric analysis of the autoradiographs demonstrated the presence of an approximately 80- to 85-kDa molecular form of the receptor as a major component under both reducing and nonreducing conditions. These results indicated that the receptor molecule is a single subunit without multiple chains covalently attached by disulfide bonding.
- 1 May 1990
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 258 (5) , G803-G809
Molecular characterization of bombesin receptors on rat pancreatic acinar AR42J cells
A biologically active, chemically defined, radioactive ligand was used for characterizing bombesin (BBS) receptors on rat pancreatic acinar cancer cells (AR42J). [Tyr4]BBS, iodinated with enzymobeads and fractionated by high-performance liquid chromatography, was monitored for biological activity as evidenced by gastrin release from perfused isolated rat stomach. The monoiodinated peptide peak was greater than 95% biologically active, with a specific activity of greater than 2,000 disintegrations.min-1.fmol-1. The maximum number of BBS receptors per cell were measured at 30 degrees C after 20-25 min of incubation; binding was submaximum at temperatures lower or higher than 30 degrees C. A single class of high-affinity binding sites (Kd = 1.77 +/- 0.21 nM) was identified for BBS on AR42J cells and nonspecific binding was less than 20-30% at all points. A total of 1.47 +/- 0.14 x 10(5) specific BBS binding sites per cell were measured that were specific for BBS and gastrin-releasing peptide (GRP) analogues. Iodinated GRP-(1-27) was cross-linked to BBS receptors on AR42J cells using several bifunctional cross-linking reagents followed by polyacrylamide gel electrophoresis of the solubilized receptor complex under reducing and nonreducing conditions. A densitometric analysis of the autoradiographs demonstrated the presence of an approximately 80- to 85-kDa molecular form of the receptor as a major component under both reducing and nonreducing conditions. These results indicated that the receptor molecule is a single subunit without multiple chains covalently attached by disulfide bonding.